{
      "Rank": 24,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [
            "Yes"
      ],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "patients will be switched from Tacrolimus to Sirolimus",
            "Patient will stay on Tacrolimus"
      ],
      "ArmGroupInterventionName": [
            "Drug: Sirolimus",
            "Drug: Tacrolimus"
      ],
      "ArmGroupLabel": [
            "Sirolimus",
            "Tacrolimus"
      ],
      "ArmGroupType": [
            "Active Comparator",
            "No Intervention"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [
            "<=18 years",
            "Between 18 and 65 years",
            ">=65 years",
            "Female",
            "Male"
      ],
      "BaselineClassDenomCountGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002"
      ],
      "NCTId": [
            "NCT01166724"
      ],
      "BaselineClassDenomCountValue": [
            "7",
            "5",
            "12",
            "7",
            "5",
            "12",
            "0",
            "0",
            "0"
      ],
      "BaselineClassDenomUnits": [
            "Participants",
            "Participants",
            "Participants"
      ],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineDenomCountValue": [
            "7",
            "5",
            "12"
      ],
      "BaselineDenomUnits": [
            "Participants"
      ],
      "BaselineGroupDescription": [
            "patients will be switched from Tacrolimus to Sirolimus\n\nSirolumus: Tacrolimus to Sirolimus\n\nTacrolimus: dosage per trough level",
            "Patient will stay on Tacrolimus",
            "Total of all reporting groups"
      ],
      "BaselineGroupId": [
            "BG000",
            "BG001",
            "BG002"
      ],
      "BaselineGroupTitle": [
            "Sirolimus",
            "Tacrolimus",
            "Total"
      ],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [
            "Count of Participants",
            "Count of Participants",
            "Count of Participants"
      ],
      "BaselineMeasurePopulationDescription": [
            "Race and Ethnicity were not collected from any participant."
      ],
      "BaselineMeasureTitle": [
            "Age, Categorical",
            "Sex: Female, Male",
            "Race and Ethnicity Not Collected"
      ],
      "BaselineMeasureUnitOfMeasure": [
            "Participants",
            "Participants",
            "Participants"
      ],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG000",
            "BG001",
            "BG002",
            "BG002"
      ],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [
            "0",
            "0",
            "0",
            "6",
            "5",
            "11",
            "1",
            "0",
            "1",
            "2",
            "3",
            "5",
            "5",
            "2",
            "7",
            "0"
      ],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The investigators hypothesize that Tacrolimus (Tac) withdrawal from a Tac, MMF and steroid based triple therapy regimen leads to long term improved/stabilized graft function (glomerular filtration rate, GFR) primarily as a consequence of halting CNI-induced fibrogenetic processes that mediate loss of functioning renal tissue. The investigators further hypothesize that the underlying fibrotic mechanism is mediated by pathophysiologic processes that promote epithelial to mesenchymal transition (EMT) (mediated by TGF- \u0192\u00d2) and that early therapeutic intervention may reverse this process (mediated by BMP-7)4.\n\nTo address these hypotheses the investigators propose the following clinical and mechanistic aims:\n\nThe investigators will test the hypothesis that switching from Tac to SRL in a Tac based triple therapy regimen with MMF and steroids in living and or deceased donor renal transplant recipients leads to improvement in allograft structure and function at 2 years post-transplantation.\n\nThe investigators will test this hypothesis in an open label controlled trial where stable renal allograft recipients on Tac, MMF, prednisone maintenance immunosuppression will undergo renal biopsy at 3-4 months post-transplantation and will be randomized to either a) Remain on Tac, MMF and prednisone (CNI-maintenance) or b) switch the Tac to SRL and continue MMF and prednisone. The investigators will then compare biopsy derived measures of allograft fibrosis (CADI, Sirius Red, Banff Chronicity Index) and GFR in the two groups"
      ],
      "BriefTitle": [
            "Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "INDUSTRY"
      ],
      "CollaboratorName": [
            "Pfizer"
      ],
      "CompletionDate": [
            "December 2014"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Kidney Transplant"
      ],
      "ConditionAncestorId": [],
      "ConditionAncestorTerm": [],
      "ConditionBrowseBranchAbbrev": [],
      "ConditionBrowseBranchName": [],
      "ConditionBrowseLeafAsFound": [],
      "ConditionBrowseLeafId": [],
      "ConditionBrowseLeafName": [],
      "ConditionBrowseLeafRelevance": [],
      "ConditionMeshId": [],
      "ConditionMeshTerm": [],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "We will test this hypothesis in an open label controlled trial where stable renal allograft recipients on Tac, MMF, prednisone maintenance immunosuppression will undergo renal biopsy at 3-4 months post-transplantation and will be randomized to either a) Remain on Tac, MMF and prednisone (CNI-maintenance) or b) switch the Tac to SRL and continue MMF and prednisone. We will then compare biopsy derived measures of allograft fibrosis (CADI, Sirius Red, Banff Chronicity Index) and GFR in the two groups"
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nAbsence of clinical acute rejection in post-transplant period preceding randomization\nHLA-mismatched solitary first and second kidney transplant recipients\nAbsence of any degree of rejection (Banff 2007) on renal biopsy at 3-6 months(+/- 2 months) post-transplant.\nAbsence of post-transplant donor-specific antibody\n\nExclusion Criteria:\n\nHLA-identical transplants\nContraindication or inability to undergo renal biopsy, like previous complications due to biopsies, anticoagulation, active infection, etc.\nPositive flow cross match, sensitized recipient, presence of donor-specific antibody.\nRejection episode after transplantation, either cellular or humoral on for cause or renal biopsy.\nRejection present on pre-randomization renal biopsy.\nProteinuria greater than 0.3 gram/day\nNative kidney disease biopsy proven or likely glomerulonephritis, primary or recurrent FSGS, MPGN or primary or recurrent membranous GN.\nHypertriglyceridemia > 400 mg/dL (treated), LDL cholesterol > 160 mg/dL while on optimal treatment.\nWBC < 2000/mm3, ANC < 1000 mm3, Platelet count < 100,000 mm3\nActive wound issues.\nPrimary non-function.\nActive BKV or CMV disease.\nEvidence of recurrent disease.\nActive infection\nPregnancy\nWomen of childbearing potential unable or unwilling to use birth control during the study.\ne GFR \u2264 40 ml/ min at screening"
      ],
      "EnrollmentCount": [
            "12"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [
            "patients will be switched from Tacrolimus to Sirolimus\n\nSirolumus: Tacrolimus to Sirolimus\n\nTacrolimus: dosage per trough level",
            "Patient will stay on Tacrolimus"
      ],
      "EventGroupId": [
            "EG000",
            "EG001"
      ],
      "EventGroupOtherNumAffected": [
            "4",
            "0"
      ],
      "EventGroupOtherNumAtRisk": [
            "7",
            "5"
      ],
      "EventGroupSeriousNumAffected": [
            "2",
            "0"
      ],
      "EventGroupSeriousNumAtRisk": [
            "7",
            "5"
      ],
      "EventGroupTitle": [
            "Sirolimus",
            "Tacrolimus"
      ],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [
            "0"
      ],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [
            "FG000",
            "FG001",
            "FG000",
            "FG001",
            "FG000",
            "FG001"
      ],
      "FlowAchievementNumSubjects": [
            "7",
            "5",
            "0",
            "0",
            "7",
            "5"
      ],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [
            "patients will be switched from Tacrolimus to Sirolimus\n\nSirolumus: Tacrolimus to Sirolimus\n\nTacrolimus: dosage per trough level",
            "Patient will stay on Tacrolimus"
      ],
      "FlowGroupId": [
            "FG000",
            "FG001"
      ],
      "FlowGroupTitle": [
            "Sirolimus",
            "Tacrolimus"
      ],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [
            "STARTED",
            "COMPLETED",
            "NOT COMPLETED"
      ],
      "FlowPeriodTitle": [
            "Overall Study"
      ],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000007166",
            "D000007155",
            "D000045505",
            "D000065095",
            "D000004791",
            "D000045504",
            "D000000900",
            "D000000890",
            "D000000903",
            "D000000970",
            "D000000935"
      ],
      "InterventionAncestorTerm": [
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Physiological Effects of Drugs",
            "Calcineurin Inhibitors",
            "Enzyme Inhibitors",
            "Molecular Mechanisms of Pharmacological Action",
            "Anti-Bacterial Agents",
            "Anti-Infective Agents",
            "Antibiotics, Antineoplastic",
            "Antineoplastic Agents",
            "Antifungal Agents"
      ],
      "InterventionArmGroupLabel": [
            "Sirolimus",
            "Sirolimus"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "ANeo",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Antineoplastic Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Laparoscopic",
            "Cardiac"
      ],
      "InterventionBrowseLeafId": [
            "M21113",
            "M18102",
            "M9364",
            "M9353",
            "M29605",
            "M3374",
            "M3366",
            "M3376",
            "M3406",
            "M5404",
            "M10948"
      ],
      "InterventionBrowseLeafName": [
            "Sirolimus",
            "Tacrolimus",
            "Immunosuppressive Agents",
            "Immunologic Factors",
            "Calcineurin Inhibitors",
            "Anti-Bacterial Agents",
            "Anti-Infective Agents",
            "Antibiotics, Antitubercular",
            "Antifungal Agents",
            "Clotrimazole",
            "Miconazole"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Tacrolimus to Sirolimus",
            "dosage per trough level"
      ],
      "InterventionMeshId": [
            "D000020123",
            "D000016559"
      ],
      "InterventionMeshTerm": [
            "Sirolimus",
            "Tacrolimus"
      ],
      "InterventionName": [
            "Sirolimus",
            "Tacrolimus"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Kidney transplant"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "June 7, 2017"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "May 9, 2017"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "The Cleveland Clinic"
      ],
      "LimitationsAndCaveatsDescription": [
            "Early termination; Sponsor discontinued the study for corporate reasons. No data analyzed."
      ],
      "LocationCity": [
            "Cleveland"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States"
      ],
      "LocationFacility": [
            "Cleveland Clinic"
      ],
      "LocationState": [
            "Ohio"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "44195"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression- Clinical and Mechanistic Impact"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "The Cleveland Clinic"
      ],
      "OrgStudyId": [
            "09-702"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [
            "General disorders",
            "Gastrointestinal disorders",
            "Metabolism and nutrition disorders",
            "General disorders"
      ],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "OtherEventStatsNumAffected": [
            "1",
            "0",
            "1",
            "0",
            "1",
            "0",
            "1",
            "0"
      ],
      "OtherEventStatsNumAtRisk": [
            "7",
            "5",
            "7",
            "5",
            "7",
            "5",
            "7",
            "5"
      ],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [
            "ER Admit: Fever, Vomitting",
            "Food Poisoning",
            "Dehydration",
            "Fever, Cough"
      ],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeDenomCountValue": [
            "0",
            "0",
            "0",
            "0"
      ],
      "OutcomeDenomUnits": [
            "Participants",
            "Participants"
      ],
      "OutcomeGroupDescription": [
            "patients will be switched from Tacrolimus to Sirolimus\n\nSirolumus: Tacrolimus to Sirolimus\n\nTacrolimus: dosage per trough level",
            "Patient will stay on Tacrolimus",
            "patients will be switched from Tacrolimus to Sirolimus\n\nSirolumus: Tacrolimus to Sirolimus\n\nTacrolimus: dosage per trough level",
            "Patient will stay on Tacrolimus"
      ],
      "OutcomeGroupId": [
            "OG000",
            "OG001",
            "OG000",
            "OG001"
      ],
      "OutcomeGroupTitle": [
            "Sirolimus",
            "Tacrolimus",
            "Sirolimus",
            "Tacrolimus"
      ],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [
            "The primary analyses will compare biopsy-derived measures of fibrosis in the Tac-maintenance and SRL groups using the t-test.",
            "We will also compare the change in iGFR (as well as estimated GFR) from time of conversion to 12 and 24 months of follow up by paired t-test between groups."
      ],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [
            "Early termination; Sponsor discontinued the study for corporate reasons. No data analyzed. Data were not collected and the outcome measure was not analyzed.",
            "Early termination; Sponsor discontinued the study for corporate reasons. No data analyzed. Data were not collected and the outcome measure was not analyzed."
      ],
      "OutcomeMeasureReportingStatus": [
            "Posted",
            "Posted"
      ],
      "OutcomeMeasureTimeFrame": [
            "12 months",
            "12 months"
      ],
      "OutcomeMeasureTitle": [
            "Biopsy-derived Measures of Fibrosis",
            "Change in iGFR"
      ],
      "OutcomeMeasureType": [
            "Primary",
            "Secondary"
      ],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "The Cleveland Clinic"
      ],
      "OverallOfficialName": [
            "T Srinivas, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Terminated"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 3"
      ],
      "PointOfContactEMail": [
            "FLECHNS@ccf.org"
      ],
      "PointOfContactOrganization": [
            "Cleveland Clinic"
      ],
      "PointOfContactPhone": [
            "216 445-5772"
      ],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [
            "Dr. Stuart Flechner"
      ],
      "PrimaryCompletionDate": [
            "December 2014"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "The primary analyses will compare biopsy-derived measures of fibrosis in the Tac-maintenance and SRL groups using the t-test."
      ],
      "PrimaryOutcomeMeasure": [
            "Biopsy-derived Measures of Fibrosis"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 months"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [
            "June 7, 2017"
      ],
      "ResultsFirstPostDateType": [
            "Actual"
      ],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [
            "February 14, 2017"
      ],
      "ResultsFirstSubmitQCDate": [
            "May 9, 2017"
      ],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "We will also compare the change in iGFR (as well as estimated GFR) from time of conversion to 12 and 24 months of follow up by paired t-test between groups."
      ],
      "SecondaryOutcomeMeasure": [
            "Change in iGFR"
      ],
      "SecondaryOutcomeTimeFrame": [
            "12 months"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [
            "Endocrine disorders",
            "General disorders"
      ],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [
            "EG000",
            "EG001",
            "EG000",
            "EG001"
      ],
      "SeriousEventStatsNumAffected": [
            "1",
            "0",
            "1",
            "0"
      ],
      "SeriousEventStatsNumAtRisk": [
            "7",
            "5",
            "7",
            "5"
      ],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [
            "Pruritus; Pancreatitis",
            "ER Admit: Fever, Vomitting"
      ],
      "StartDate": [
            "July 2010"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "February 2017"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "July 21, 2010"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "July 20, 2010"
      ],
      "StudyFirstSubmitQCDate": [
            "July 20, 2010"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": [
            "Collaborator stopped study"
      ]
}